A team of researchers is conducting studies on the role of a vaccine in preventing colorectal cancer in individuals having lynch syndrome.
A team of researchers is working hard upon coming up with a vaccine that might prevent cancer in individuals having Lynch Syndrome. Lynch syndrome is an inherent condition known for elevating the overall risk of developing endometrial, colorectal, and other types of cancers.
The Study Involving the Development of the Vaccine
The team of scientists was led by Steven Lipkin –a leading MD & Ph.D. at Weill Cornell Medicine. The team presented the reports from the tests conducted on the development of a cancer-preventing vaccine that received the funding from NCI at the latest meeting. The vaccine was aimed at preventing the growth of colorectal tumors in the mice sample having Lynch Syndrome. The vaccine also supported the prolonged life by extending the survival rate of the mice in comparison to the mice that were unvaccinated.
During a press briefing, Dr. Lipkin claimed that the overall simplicity of the given approach implies that the test might be promising for taking forward the development of the human vaccine. The press briefing was organized on 1st April at the annual meeting of the American Association for Cancer Research in Atlanta.
Development & Optimization of the Cancer Vaccine
Towards developing the neoantigen vaccine for human samples, Dr. Lipkin, along with his colleagues, has made plans to come across shared neo-antigens occurring during the early stage of colorectal cancer of patients having Lynch Syndrome. The project was awarded funding by NCI through the Cancer Moonshot Translational Network of Immuno-Oncology.
When the human trials for the development of a vaccine that helps in cancer prevention will move forward, Dr. Lipkin stated that it might take several years towards determining whether or not it will work.
During the meantime, Dr. Lipkin and his team aim at using the respective mice sample towards getting a better understanding of exactly how the vaccine would work. The team also aims at analyzing the ways in which the growing cancer cells might become resistant to the effects of the vaccine.